Berceanu Vaduva Marcel Mihai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Berceanu Vaduva Marcel Mihai has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Abhinav Sharma
Doctoral School, “Victor Babes” University of Medicine and Pharmacy, 3000041 Timisoara, Romania
3 shared publications - Nilima Rajpal Kundnani
Department VI—Cardiology, “Victor Babeş” University of Medicine and Pharmacy, 300041 Timisoara, Romania
3 shared publications - Lucretia Marin-Bancila
Faculty of Medicine, “Victor Babeș” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, 300041 Timișoara, Romania
2 shared publications - Mihaela Valcovici
Department VI-Cardiology, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
2 shared publications - Abhijit Kumar
Department of Anaesthesiology, All India Institute of Medical Sciences, Kalyani, West Bengal, India
1 shared publication - Ana-Maria Pah
Department of Cardiology, “Victor Babeș” University of Medicine and Pharmacy of Timișoara, Eftimie Murgu Square 2, 300041 Timișoara, Romania
1 shared publication
Latest Publications
- Open Access
Impact of Early Diagnosis and Immunosuppressive Therapy on Giant Cell Myocarditis Outcomes: A Review
Background: Giant cell myocarditis (GCM) is a rare condition with an incompletely understood immune pathogenesis, characterized by inflammatory damage to the myocardium and the presence of multinucleated giant cells on histopathological examination. The frequently fulminant and severe course requires rapid intervention for a correct diagnosis and the initiation of immunosuppressive therapy, which is often life-saving. Materials and methods: This article contains information from observational studies and case reports, systematically collected from prestigious publications such as JACC, NEJN, ESC, JCC, Heliyon, and Cureus found in the PubMed and ClinicalTrials.gov databases. Thus, 25 patients diagnosed with giant cell myocarditis between March 2019 and May 2025 were analyzed, with a focus not only on the initial clinical evolution, mortality incidence, and the need for heart transplantation but also on the incidence of major complications such as cardiogenic shock and malignant rhythm and conduction disorders refractory to drug treatment. These parameters were studied according to certain intrinsic factors that cannot be influenced, such as age at onset, gender, and associated pathology of the patient, as well as extrinsic factors that can be influenced, such as the time of diagnosis and the start of immunosuppressive therapy. The results obtained were compared with those in the literature from previous years, considering the limitations of the current study. Results: The selected patients were 13 women (52%) and 12 men (48%), mostly from the US and Japan, aged between 22 and 76 years, with an average age of 44.92 years. An associated autoimmune pathology was found in 40% of patients in this group, and previous cardiovascular pathology in 28%. Only 8% had a history of GCM. The clinical onset of new-onset heart failure, refractory to usual therapy, with progressive dyspnea as the cardinal symptom was found in 12 patients, representing 48% of cases; palpitations as an expression of rhythm or conduction disorders were found in five patients, representing 20%; precordial discomfort to precordial pain accompanied or not by ST-T segment changes was present in four patients, representing 16%; and general signs and symptoms or those of other organs were present in three (12%) cases. The diagnosis was made by histological examination of the biopsy fragment obtained by endomyocardial biopsy or from the myocardial fragment obtained during the implantation of mechanical cardiovascular support devices and, less frequently, on the explanted heart and at autopsy. In terms of progression, of the 25 patients, four (16%) died, four (16%) required heart transplantation, and 16 (64%) had a severe progression with cardiogenic shock, which required mechanical circulatory support in 11 (44%) cases. The outcome was mainly influenced by the early diagnosis and administration of immunosuppressive medication, but also by the age of the patients and associated chronic diseases. Conclusions: Giant cell myocarditis is a serious condition that, in the absence of rapid diagnosis and appropriate immunosuppressive therapy, has a fulminant, often fatal course. Clinical suspicion of giant cell myocarditis remains important in the initial diagnosis. Raising this suspicion, together with modern and improved paraclinical investigations compared to previous years, has led to faster diagnosis and administration of immunosuppressive therapy in this pathology. Histological examination remains the gold standard for final diagnosis, but it should be noted that it may be non-diagnostic. In the face of a strong suspicion of giant cell myocarditis, the best approach is to start immunosuppressive therapy and monitor the patient’s progress. Immunosuppressive treatment remains decisive in influencing the evolution of this condition, both through prompt administration and through the adaptation of therapeutic regimens to the evolution of patients. A more detailed understanding of the immune-mediated pathogenesis of GCM and the identification of clinical risk factors for unfavorable short- and long-term outcomes may enable earlier risk stratification and the development of more targeted, individualized therapeutic strategies.
Open AccessImpact of Early Diagnosis and Immunosuppressive Therapy on Giant Cell Myocarditis Outcomes: A Review
Background: Giant cell myocarditis (GCM) is a rare condition with an incompletely understood immune pathogenesis, characterized by inflammatory damage to the myocardium and the presence of multinucleated giant cells on histopathological examination. The frequently fulminant and severe course requires rapid intervention for a correct diagnosis and the initiation of immunosuppressive therapy, which is often life-saving. Materials and methods: This article contains information from observational studies and case reports, systematically collected from prestigious publications such as JACC, NEJN, ESC, JCC, Heliyon, and Cureus found in the PubMed and ClinicalTrials.gov databases. Thus, 25 patients diagnosed with giant cell myocarditis between March 2019 and May 2025 were analyzed, with a focus not only on the initial clinical evolution, mortality incidence, and the need for heart transplantation but also on the incidence of major complications such as cardiogenic shock and malignant rhythm and conduction disorders refractory to drug treatment. These parameters were studied according to certain intrinsic factors that cannot be influenced, such as age at onset, gender, and associated pathology of the patient, as well as extrinsic factors that can be influenced, such as the time of diagnosis and the start of immunosuppressive therapy. The results obtained were compared with those in the literature from previous years, considering the limitations of the current study. Results: The selected patients were 13 women (52%) and 12 men (48%), mostly from the US and Japan, aged between 22 and 76 years, with an average age of 44.92 years. An associated autoimmune pathology was found in 40% of patients in this group, and previous cardiovascular pathology in 28%. Only 8% had a history of GCM. The clinical onset of new-onset heart failure, refractory to usual therapy, with progressive dyspnea as the cardinal symptom was found in 12 patients, representing 48% of cases; palpitations as an expression of rhythm or conduction disorders were found in five patients, representing 20%; precordial discomfort to precordial pain accompanied or not by ST-T segment changes was present in four patients, representing 16%; and general signs and symptoms or those of other organs were present in three (12%) cases. The diagnosis was made by histological examination of the biopsy fragment obtained by endomyocardial biopsy or from the myocardial fragment obtained during the implantation of mechanical cardiovascular support devices and, less frequently, on the explanted heart and at autopsy. In terms of progression, of the 25 patients, four (16%) died, four (16%) required heart transplantation, and 16 (64%) had a severe progression with cardiogenic shock, which required mechanical circulatory support in 11 (44%) cases. The outcome was mainly influenced by the early diagnosis and administration of immunosuppressive medication, but also by the age of the patients and associated chronic diseases. Conclusions: Giant cell myocarditis is a serious condition that, in the absence of rapid diagnosis and appropriate immunosuppressive therapy, has a fulminant, often fatal course. Clinical suspicion of giant cell myocarditis remains important in the initial diagnosis. Raising this suspicion, together with modern and improved paraclinical investigations compared to previous years, has led to faster diagnosis and administration of immunosuppressive therapy in this pathology. Histological examination remains the gold standard for final diagnosis, but it should be noted that it may be non-diagnostic. In the face of a strong suspicion of giant cell myocarditis, the best approach is to start immunosuppressive therapy and monitor the patient’s progress. Immunosuppressive treatment remains decisive in influencing the evolution of this condition, both through prompt administration and through the adaptation of therapeutic regimens to the evolution of patients. A more detailed understanding of the immune-mediated pathogenesis of GCM and the identification of clinical risk factors for unfavorable short- and long-term outcomes may enable earlier risk stratification and the development of more targeted, individualized therapeutic strategies.
- Open Access
- 28 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 773
Genus Klebsiella: Infections Encountered in a General Surgery Department and Antimicrobial Drugs Susceptibility Patterns
Klebsiella species, particularly Klebsiella pneumoniae, are among the most frequently isolated Gram-negative pathogens in surgical departments, associated with a growing trend in multidrug resistance. To identify the types of infections caused by Klebsiella spp. in a general surgery department and to analyze their antimicrobial susceptibility patterns. This retrospective observational study includes bacteriological cultures collected from surgical inpatients between October 2016 and December 2024. Only cases with confirmed Klebsiella spp. isolation were included. Specimen types, infection categories, and antibiotic susceptibility profiles were extracted and analyzed. A total of 138 Klebsiella-positive cultures were identified. Clinical characteristics were analyzed in 38 patients with complete records. The most common infection types included surgical site infections (SSIs), intra-abdominal infections, and biliary tract infections. Sensitivity was highest to carbapenems, while marked resistance was observed to ampicillin-sulbactam and third-generation cephalosporins. Some isolates exhibited ESBL or carbapenemase-producing phenotypes. Reported colistin non-susceptibility was elevated in our cohort; however, these results should be interpreted cautiously because the reference broth microdilution method was not systematically documented. The findings underscore the importance of local surveillance of Klebsiella spp. in surgical settings to info rm empirical treatment and control the spread of multidrug-resistant organisms.
- 28 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 773
Open AccessGenus Klebsiella: Infections Encountered in a General Surgery Department and Antimicrobial Drugs Susceptibility Patterns
Klebsiella species, particularly Klebsiella pneumoniae, are among the most frequently isolated Gram-negative pathogens in surgical departments, associated with a growing trend in multidrug resistance. To identify the types of infections caused by Klebsiella spp. in a general surgery department and to analyze their antimicrobial susceptibility patterns. This retrospective observational study includes bacteriological cultures collected from surgical inpatients between October 2016 and December 2024. Only cases with confirmed Klebsiella spp. isolation were included. Specimen types, infection categories, and antibiotic susceptibility profiles were extracted and analyzed. A total of 138 Klebsiella-positive cultures were identified. Clinical characteristics were analyzed in 38 patients with complete records. The most common infection types included surgical site infections (SSIs), intra-abdominal infections, and biliary tract infections. Sensitivity was highest to carbapenems, while marked resistance was observed to ampicillin-sulbactam and third-generation cephalosporins. Some isolates exhibited ESBL or carbapenemase-producing phenotypes. Reported colistin non-susceptibility was elevated in our cohort; however, these results should be interpreted cautiously because the reference broth microdilution method was not systematically documented. The findings underscore the importance of local surveillance of Klebsiella spp. in surgical settings to info rm empirical treatment and control the spread of multidrug-resistant organisms.
- Open Access
The Junction of Allergic Inflammation and Atherosclerosis: Pathways and Clinical Implications—A Review
Background: Cardiovascular disorders, especially atherosclerosis, have been associated with allergic inflammation. In addition to traditional inflammatory responses, there is evidence that the development and instability of coronary artery plaque may be influenced by effector cells of allergic inflammation. This review examines the phases of allergic pathology, the immunological mechanisms of atherosclerosis, and the clinical link between allergic diseases (asthma, atopic dermatitis, allergic rhinitis, and food allergy) and cardiovascular disease (CVD), along with future therapeutic perspectives. Material and Method: A literature search was conducted in PubMed, Google scholar; ScienceDirect, Scopus, and studies published between 2014–2024 were taken into consideration. Keywords included allergic inflammation, eosinophils, mast cells, reactive oxygen species, atherosclerosis, Th2 cells, and cytokines. Epidemiological studies and review articles were included. Results: Emerging evidence suggests that allergic inflammation contributes to atherosclerosis through interconnected mechanisms such as eosinophil activation, reactive oxygen species production, mast cell degranulation, and endothelial dysfunction. Th2-driven immune responses, which are mediated by cytokines such as IL-4, IL-5, and IL-13, as well as eosinophil activity and mast cell degranulation, play a crucial role in vascular inflammation and plaque progression. Additionally, changes in lipid metabolism contribute to this process. Epidemiological studies support this connection, indicating that patients with chronic allergic conditions such as asthma, allergic rhinitis, food allergy, and atopic dermatitis experience increased cardiovascular morbidity. However, most current data are observational, and our understanding of the underlying mechanisms in humans remains limited, often relying on insights gained from preclinical models. Conclusions: A potential mechanism for cardiovascular risk is suggested by the interaction between atherosclerosis and allergic inflammation. Promising alternatives for treating allergic inflammation and cardiovascular issues include novel treatments like cytokine inhibitors, mast cell stabilizers, and biologics that target certain pathways. Further research is necessary to see whether concentrating on allergy pathways could lead to innovative treatments for cardiovascular disorders or vice versa.
Open AccessThe Junction of Allergic Inflammation and Atherosclerosis: Pathways and Clinical Implications—A Review
Background: Cardiovascular disorders, especially atherosclerosis, have been associated with allergic inflammation. In addition to traditional inflammatory responses, there is evidence that the development and instability of coronary artery plaque may be influenced by effector cells of allergic inflammation. This review examines the phases of allergic pathology, the immunological mechanisms of atherosclerosis, and the clinical link between allergic diseases (asthma, atopic dermatitis, allergic rhinitis, and food allergy) and cardiovascular disease (CVD), along with future therapeutic perspectives. Material and Method: A literature search was conducted in PubMed, Google scholar; ScienceDirect, Scopus, and studies published between 2014–2024 were taken into consideration. Keywords included allergic inflammation, eosinophils, mast cells, reactive oxygen species, atherosclerosis, Th2 cells, and cytokines. Epidemiological studies and review articles were included. Results: Emerging evidence suggests that allergic inflammation contributes to atherosclerosis through interconnected mechanisms such as eosinophil activation, reactive oxygen species production, mast cell degranulation, and endothelial dysfunction. Th2-driven immune responses, which are mediated by cytokines such as IL-4, IL-5, and IL-13, as well as eosinophil activity and mast cell degranulation, play a crucial role in vascular inflammation and plaque progression. Additionally, changes in lipid metabolism contribute to this process. Epidemiological studies support this connection, indicating that patients with chronic allergic conditions such as asthma, allergic rhinitis, food allergy, and atopic dermatitis experience increased cardiovascular morbidity. However, most current data are observational, and our understanding of the underlying mechanisms in humans remains limited, often relying on insights gained from preclinical models. Conclusions: A potential mechanism for cardiovascular risk is suggested by the interaction between atherosclerosis and allergic inflammation. Promising alternatives for treating allergic inflammation and cardiovascular issues include novel treatments like cytokine inhibitors, mast cell stabilizers, and biologics that target certain pathways. Further research is necessary to see whether concentrating on allergy pathways could lead to innovative treatments for cardiovascular disorders or vice versa.
- Open Access
- 24 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 785
Enhancing Quality of Life in Patients with Acute Wounds: The Synergistic Effects of Negative Pressure Wound Therapy and Physiotherapy
Background and Objectives: Negative Pressure Wound Therapy (NPWT) is widely used in acute wound management, promoting tissue regeneration and edema reduction. However, the effects of integrating physiotherapy on functional recovery and quality of life remain underexplored. This study assesses the combined impact of NPWT and physiotherapy on functional and clinical outcomes in patients with acute wounds at the Timișoara County Emergency Clinical Hospital. Methods: This cross-sectional study included 205 patients divided into two groups: NPWT-only (n = 110) and NPWT plus physiotherapy (n = 95). Clinical and functional parameters, including joint mobility, edema, and pain, were assessed at baseline, ten days, six weeks, and six months. Quality of life and mental health were evaluated using WHOQOL-BREF, SF-36, VAS, and HADS questionnaires. Results: Compared to NPWT alone, the NPWT + physiotherapy group showed at discharge greater edema reduction (40.58 ± 2.48 vs. 41.15 ± 2.39), improved joint mobility (14.22 ± 1.66° vs. 10.05 ± 1.76°, p < 0.05), and a more significant pain decrease (VAS reduction to 5.68 ± 1.13 vs. 6.7 ± 1.05, p < 0.001). Quality of life scores improved notably, with higher WHOQOL-BREF (59.89 ± 5.86 vs. 66.64 ± 6.24, p < 0.001) and HADS psychological scores (p < 0.001). Conclusions: Combining NPWT with physiotherapy enhances functional recovery, reduces pain and anxiety, and improves quality of life. These findings support a multidisciplinary approach in acute wound management.
- 24 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 785
Open AccessEnhancing Quality of Life in Patients with Acute Wounds: The Synergistic Effects of Negative Pressure Wound Therapy and Physiotherapy
Background and Objectives: Negative Pressure Wound Therapy (NPWT) is widely used in acute wound management, promoting tissue regeneration and edema reduction. However, the effects of integrating physiotherapy on functional recovery and quality of life remain underexplored. This study assesses the combined impact of NPWT and physiotherapy on functional and clinical outcomes in patients with acute wounds at the Timișoara County Emergency Clinical Hospital. Methods: This cross-sectional study included 205 patients divided into two groups: NPWT-only (n = 110) and NPWT plus physiotherapy (n = 95). Clinical and functional parameters, including joint mobility, edema, and pain, were assessed at baseline, ten days, six weeks, and six months. Quality of life and mental health were evaluated using WHOQOL-BREF, SF-36, VAS, and HADS questionnaires. Results: Compared to NPWT alone, the NPWT + physiotherapy group showed at discharge greater edema reduction (40.58 ± 2.48 vs. 41.15 ± 2.39), improved joint mobility (14.22 ± 1.66° vs. 10.05 ± 1.76°, p < 0.05), and a more significant pain decrease (VAS reduction to 5.68 ± 1.13 vs. 6.7 ± 1.05, p < 0.001). Quality of life scores improved notably, with higher WHOQOL-BREF (59.89 ± 5.86 vs. 66.64 ± 6.24, p < 0.001) and HADS psychological scores (p < 0.001). Conclusions: Combining NPWT with physiotherapy enhances functional recovery, reduces pain and anxiety, and improves quality of life. These findings support a multidisciplinary approach in acute wound management.